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Summary
bZip and bHLHZip protein family members comprise
a large fraction of eukaryotic transcription factors
and need to bind DNA in order to exert most of their
fundamental biological roles. Their binding to DNA re-
quires homo- or heterodimerization via a-helical do-
mains, which generally do not contain obvious bind-
ing sites for small molecules. We have identified two
small molecules, dubbed Mycro1 and Mycro2, which
inhibit the protein-protein interactions between the
bHLHZip proteins c-Myc and Max. Mycros are the first
inhibitors of c-Myc/Max dimerization, which have been
demonstrated to inhibit DNA binding of c-Myc with
preference over other dimeric transcription factors
in vitro. Mycros inhibit c-Myc-dependent proliferation,
gene transcription, and oncogenic transformation in
the low micromolar concentration range. Our data
support the idea that dimeric transcription factors
can be druggable even in the absence of obvious
small-molecule binding pockets.
Introduction
Aberrantly high levels of the transcription factor c-Myc
are found in most human cancers and have been linked
to one out of seven cancer deaths in the United States.
[1]. The transcription factor c-Myc is involved in funda-
mental cellular processes including cell cycle progres-
sion, growth, oncogenic transformation, and apoptosis
[2–5]. Its expression and posttranscriptional stabiliza-
tion are tightly regulated upon induction by growth stim-
ulatory signals. Conditional overexpression of c-Myc
in genetic model systems leads to tumorigenesis, which
can be reverted by inactivation of the c-Myc transgene
[6–9]. This suggests that inactivation of c-Myc may
be a novel approach toward the treatment of human
cancers, which display increased activities of c-Myc,
e.g., lung, colon, and breast carcinomas, or Burkitt’s
lymphoma.
*Correspondence: berg@biochem.mpg.dec-Myc is a member of the basic helix-loop-helix leu-
cine zipper protein family. All known biological activities
of c-Myc require heterodimerization with its activation
partner Max [10] from the same protein family. c-Myc
regulates up to 15% of all genes in an organism [11] by
two mechanisms: first, binding of c-Myc/Max hetero-
dimers to specific recognition sites (E-box elements)
within promoter regions activates gene transcription,
and second, indirect recruitment of c-Myc/Max dimers
to DNA via the zinc-finger protein Miz-1 leads to repres-
sion of c-Myc-regulated genes [12, 13]. Therefore, the
most direct and thorough approach toward the inhibition
of c-Myc functions involves the inhibition of the protein-
protein interactions required for association of c-Myc
with its binding partner Max, both in the presence and
absence of the DNA sequence to which c-Myc/Max
binds directly (Figure 1). However, the discovery of inhib-
itors of c-Myc/Max heterodimers is hampered by the
large protein-protein interface between the two basic he-
lix-loop-helix leucine zipper (bHLHZip) proteins, consist-
ing of the second helix of the helix-loop-helix domain and
the leucine zippers (3206 A˚2 of buried interface) [14].
Additionally, and perhaps even more importantly, the
crystal structure does not reveal any obvious binding
pockets for small molecules, prohibiting any rational pre-
dictions about the nature of substances that might inhibit
c-Myc/Max dimer formation. In the light of the dramatic
stabilization of c-Myc/Max interactions by nine orders
of magnitude upon addition of DNA [15], it is conceivable
that the presence of DNA significantly impairs a com-
pound’s effectiveness toward inhibition of c-Myc/Max
association, perhaps dependent on the location of the
compound’s binding epitope. Therefore, in order to ef-
fectively inhibit the functions of c-Myc, it is of particular
importance for an inhibitor of c-Myc/Max dimerization
to maintain its inhibitory properties in the presence of
the c-Myc/Max DNA binding motif while showing prefer-
ence over the inhibition of DNA binding of other dimeric
transcription factors. However, no small molecule has
been reported to fulfill this criterion in in vitro assays
(i.e., not cell-based assays) to date.
Of the first two reported nonpeptidic inhibitors of
c-Myc/Max dimerization, referred to as IIA6B17 and
IIA4B20, only IIA6B17 maintained its inhibitory proper-
ties in the presence of DNA in vitro [16]. Unfortunately,
the activity of IIA6B17 also extended to the related basic
zipper (bZip) family protein Jun, which limits its potential
to serve as a molecular research tool. Recently, four
compounds consisting of planar and hydrophobic
chemical building blocks were reported to inhibit Myc/
Max association in the presence of DNA [17]. Two of
these compounds, referred to as NY2267 and NY2280,
inhibited c-Myc-dependent oncogenic transformation
with preference over transformation dependent on Jun
but affected gene transcription dependent on both
c-Myc and c-Jun to the same extent. Interestingly, fatty
acids have been described to inhibit DNA binding of
c-Myc [18], although contradictory statements have
been made regarding the effectiveness of inhibition by
saturated fatty acids [19]. In addition, four compounds
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746Figure 1. Inhibition of c-Myc by Inhibitors of
the c-Myc/Max Interaction
c-Myc can activate gene transcription by
direct binding of c-Myc/Max heterodimers
to specific DNA binding elements referred
to as E-box elements and can repress gene
transcription by indirect DNA binding of
c-Myc/Max dimers via the zinc-finger protein
Miz-1. Since all known biological functions of
c-Myc require binding to its activating part-
ner Max, inhibition of the interaction be-
tween c-Myc and Max by a small organic
molecule (indicated by the star) would inhibit
all known biological functions of c-Myc.structurally not related to one another were reported to
inhibit dimerization of c-Myc and Max, but data about
the compounds’ abilities to inhibit DNA binding of c-
Myc in vitro were not presented. The substances were
shown to suppress growth of c-Myc-transformed cells
in nude mice; however, no information was provided
about the compounds’ effect on anchorage-indepen-
dent growth of cell lines transformed by oncogenes other
than Myc [20]. Finally, a small molecule called ‘‘MYRA-A’’
was reported to inhibit DNA binding of Myc family pro-
teins without interfering with c-Myc/Max dimerization
[21]. In this manuscript, we detail the identification of My-
cro1 and Mycro2, the first small molecules demonstrated
to show a preference for the inhibition of the c-Myc/Max
association over the inhibition of related transcription
factors in the presence of their DNA binding motif in vitro.
Results and Discussion
Small-Molecule Inhibitors of c-Myc/Max Dimerization
and DNA Binding Identified by High-Throughput
Screening of Chemical Libraries
We have developed assays based on fluorescence
polarization, which analyzed binding of Myc/Max,
Max/Max, Jun/Jun, and C/EBPa/C/EBPa dimers to their
respective fluorophore-labeled DNA target sequences
(Figure 2A) [22]. Screening of a diverse selection of
17,298 small molecules for their abilities to disrupt bind-
ing of c-Myc/Max to a fluorescein-labeled oligonucleo-
tide containing the binding motif CACGTG (Z0 value
[23] of the assay: 0.65 6 0.07) resulted in the identifica-
tion of a small molecule dubbed Mycro1 (pronounced
‘‘mick-ro,’’ for Myc activity-reducing organic substance
and to highlight its comparably small size in relation to
the inhibited protein-protein interface) (Figure 2B). Anal-
ysis of structure-activity relationships with commer-
cially available derivatives revealed a derivative (2),
(referred to as Mycro2), which displayed similar activity
in this assay (Figures 2B–2D). Both Mycros inhibited
Myc/Max DNA binding with good activities (IC50 values:
Mycro1, 30 6 5 mM; Mycro2, 23 6 4 mM) and show pref-
erence over the inhibition of binding of Max/Max homo-dimers (59% similar) to the same DNA probe (IC50
values: Mycro1, 72 6 13 mM; Mycro2, 54 6 9 mM). DNA
binding of the related bZip proteins CEBPa and Jun,
which also requires the formation of the respective ho-
modimers, was inhibited to an even smaller extent in
the fluorescence polarization assays (Figures 2C and
2D). Like c-Myc/Max, dimerization of Max/Max,
CEBPa/CEBPa, and Jun/Jun is mediated by leucine zip-
pers, which contain four to five heptad repeats consist-
ing of hydrophobic amino acids (e.g., leucine) and polar
amino acids and mediate protein-protein interactions by
hydrophobic and electrostatic interactions. Mycros had
virtually no effect on interactions between two SH2 do-
mains and their binding partners (see Figures S1A and
S1B in the Supplemental Data online), suggesting that
the effect of Mycros on DNA binding of c-Myc/Max
and the related transcription factors results from spe-
cific interactions with the a-helical dimerization motifs.
Unfortunately, the binding site of Mycros cannot be as-
sessed by mutation or deletion experiments, as muta-
tions or deletions in the dimerization domains of c-Myc
and Max result in loss of their abilities to dimerize. A
closely related regioisomer of Mycro2 (3) (Figure 2B)
had lost virtually all activity (4% 6 13% inhibition of
c-Myc/Max DNA binding at 100 mM (3)) (see Figure S1C).
To verify the results of the fluorescence polarization
assay in a fluorescence-independent assay format, we
analyzed the molecules’ abilities to interfere with DNA
binding of c-Myc in electrophoretic mobility shift assays
(EMSA). Consistent with the results obtained in the fluo-
rescence polarization assay, both Mycros inhibited DNA
binding of c-Myc and displayed selectivity for inhibition
of DNA binding of c-Myc/Max over Jun/Fos hetero-
dimers (Figures 2E and 2F). The control compound 3,
which was inactive in the FP assay, was also inactive
in EMSA (see Figure S1D). To investigate whether the
observed reduction in DNA binding of c-Myc originates
from inhibition of the DNA-protein interaction between
c-Myc/Max dimers and DNA or from inhibition of pro-
tein-protein interactions between c-Myc and Max, we
analyzed the effect of Mycros on the interaction be-
tween CFP-tagged c-Myc and GST-tagged Max in
Myc/Max Inhibitors
747Figure 2. Mycros Inhibit DNA Binding of c-Myc by Blocking the Interaction between c-Myc and Max
(A) Binding of the transcription factor dimers c-Myc/Max, Max/Max, Jun/Jun, und C/EBPa-C/EBPa to fluorophore-labeled oligonucleotides
comprising their DNA target sequences as assessed by fluorescence polarization.
(B) Chemical structures of Mycro1 (1), Mycro2 (2), and the inactive derivative 3.
(C) Activity profile of Mycro1 against DNA binding of c-Myc/Max, Max/Max, Jun/Jun, and C/EBPa-C/EBPa as assessed by fluorescence
polarization. Error bars represent standard errors of the mean (SEM).
(D) Activity profile of Mycro2 against DNA binding of c-Myc/Max, Max/Max, Jun/Jun, and C/EBPa/C/EBPa as assessed by fluorescence
polarization. Error bars represent SEM.
(E) Activity profile of Mycro1 and Mycro2 against DNA binding of c-Myc/Max heterodimers in EMSA. All assigned lanes contain c-Myc, Max,
and labeled E box, except the first lane (labeled E Box only, no proteins) and the second lane (Max and labeled E Box, no c-Myc).
(F) Activity profile of Mycro1 and Mycro2 against DNA binding of Jun/Fos heterodimers in EMSA. All assigned lanes contain Jun, Fos, and
labeled TRE, with the exception of the first lane on each gel (labeled TRE only, no proteins) and the second lane (Jun and labeled TRE, no Fos).
(G) Mycro1 and Mycro2 inhibit the protein-protein interactions between CFP-tagged c-Myc and GST-tagged Max in a GST pull-down assay.
The anti-GFP antibody used does not discriminate between the various GFP mutants.a GST pull-down assay (Figure 2G). Both Mycros already
inhibited binding between c-Myc and Max at 10 mM,
while the negative control compound 3 had no effect.
Considering the stabilization of c-Myc/Max interactions
upon addition of DNA, the relatively low activity differ-
ences in these two assay types could be explained by
a model by which Mycros interact with the proteins,
preferentially c-Myc, and thereby lock monomeric c-
Myc in a conformation that is unable to bind to Max
and therefore also unable to bind DNA. Hence, DNA
binding would no longer represent a stabilizing factor.
The low activity of Mycros on DNA binding of Jun/Jun
(Figures 2C and 2D) and Jun/Fos (Figure 2F), and espe-
cially, the virtual absence of inhibition of the SH2-do-
main proteins STAT3 and Lck (see Figures S1A and
S1B) strongly argues against an alternative model of ex-
planation, that of unspecific protein aggregation and
precipitation. Compounds 1–3 fully comply with Lipin-
ski’s ‘‘rule of five’’ [24] and thereby fulfill an important
empirical criterion for bioavailable substances.
Mycros Inhibit Cell Proliferation and Cell Cycle
Progression in a c-Myc-Dependent Manner
Because c-Myc regulates a wide range of target genes
essential for cell function, even a small decrease in c-
Myc activity conferred by the inhibitors can be expected
to have a noticeable biological effect in cellular assays.
c-Myc is required for entry into S phase and cell cycle
progression [3, 25] of almost all cell types. Consistentwith their in vitro activities, Mycros inhibited proliferation
of the c-Myc-dependent tumor cell lines Raji (Burkitt’s
lymphoma), MCF-7 (breast carcinoma), and U-2OS (os-
teosarcoma) at 10 and 20 mM (Figures 3A–3C). Similarly,
proliferation of c-Myc-dependent NIH/3T3 cells was also
inhibited by both Mycros at 10 and 20 mM (Figure 3D). We
have not observed an increase in the number of floating
cells in the tissue culture medium upon addition of
Mycros, indicating the absence of gross toxicity. Since
complete inhibition of c-Myc in c-Myc-dependent cells
can be expected to cause cell death, the absence of tox-
icity indicates that at the concentrations used in tissue
culture (10 mM and 20 mM), Mycros only partially inhibited
c-Myc, consistent with the incomplete inhibition of
c-Myc at these concentrations observed in vitro (Fig-
ure 2). Time-dependent analysis of S-phase entry in
a BrdU incorporation assay revealed that the effect on
proliferation of NIH/3T3 cells was at least in part due to
a significant delay in S-phase entry caused by the inhib-
itors, consistent with scientific evidence linking c-Myc
activity with S-phase entry [3, 25] (Figure 3E). In contrast
to the inhibition of these four c-Myc-dependent cell lines,
proliferation of the pheochromocytoma cell line PC-12,
in which the Myc binding protein Max is rendered dys-
functional by homozygous mutation and which therefore
proliferate independent of c-Myc [26], was not inhibited
by either Mycro, indicating that the inhibition of cancer
cell proliferation by Mycros occurs via a c-Myc-depen-
dent mechanism (Figure 3F).
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748Figure 3. Mycro1 and Mycro2 Inhibit c-Myc-Dependent Cell Proliferation and Delay S-Phase Entry
Mycro1 and Mycro2 inhibit proliferation of the c-Myc-dependent cell lines U-2OS (A), MCF-7 (B), Raji (C), and NIH/3T3 (D). (E) Mycro1 and
Mycro2 delay S-phase entry as analyzed by a BrdU incorporation assay in NIH/3T3 cells. (F) Mycro1 and Mycro2 do not inhibit proliferation
of the c-Myc-independent cancer cell line PC-12. Error bars represent standard deviation (SD).Mycros Inhibit c-Myc-Dependent Gene Transcription
Genome-wide analysis of gene transcription has re-
vealed that c-Myc activates or represses a wide range
of target genes, but usually by not more than a factor
of three [11], which renders the detection of changes
in the transcription levels of target genes a difficult
task. To assess the effect of Mycros on c-Myc-induced
gene transcription, we therefore set up a reporter assay
that analyzes the effect of Mycros on the transcriptional
activity of c-Myc and other dimeric transcription factors
(see Figure S2). Both Mycro1 and Mycro2 strongly in-
hibited c-Myc-induced gene transcription at 10 mM
(Figure 4A) in HEK293 T cells cotransfected with an ex-
pression vector for c-Myc and a luciferase reporter bear-
ing four Myc/Max binding sites. The activities of Mycros
in this assay appear to be slightly higher than in the DNA
binding assays (Figures 2C–2E); however, it should be
kept in mind that the potency of any small-molecule in-
hibitor is likely to depend on the precise assay condi-
tions, especially with respect to the concentrations of
proteins, salts, or other macromolecules. Since no in vitro
assay will precisely reflect intracellular conditions, it
would be unrealistic to expect exactly the same poten-
cies of a compound in vitro as in cells. The activity of a re-
porter construct containing multiple binding sites fora subgroup of dimeric bZip transcription factors, refered
to as AP-1, was reduced to a smaller extent (Figure 4B).
AP-1 is a term for dimeric complexes that comprise
members of the Jun, Fos, ATF, and Maf protein subfam-
ilies, all of which are dimeric bZip proteins [27]. The main
AP-1 proteins in mammalian cells are Jun and Fos [28],
and the specificity of Mycro2 for Myc over AP-1 in the
luciferase assays reflects the selectivity profile for Myc
versus Jun observed in the DNA binding assays (Figures
2C–2F). Transcription dependent on dimerization of the
transcription factor serum-response factor (SRF) was
not or only slightly inhibited by Mycro1 or Mycro2,
respectively (Figure 4C). Consistent with its inactivity
in vitro, derivative 3 did not interfere with c-Myc depen-
dent transcription (Figure 4A).
Mycros Inhibit c-Myc-Dependent Anchorage-
Independent Growth
Rat1a fibroblasts can be transformed by stable overex-
pression of c-Myc (Rat1a/c-myc) or v-Src (Rat1a/v-src),
which enables them to grow anchorage independently
as colonies in soft agar. Transformation by v-Src may
be partially dependent on c-Myc [29]; however, v-Src
has also been shown to signal independently of c-Myc
[30]. Therefore, incomplete inhibition of c-Myc can beFigure 4. Mycro1 and Mycro2 Selectively Inhibit Transcription in a c-Myc-Dependent Reporter Gene Assay
(A) Mycro1 and Mycro2 inhibit c-Myc-dependent luciferase gene activation.
(B) Effect of Mycro1 and Mycro2 on transcriptional activity of the AP-1 transcription factors induced by addition of 12-O-tetradecanoylphorbol
13-acetate.
(C) Effect of Mycro1 and Mycro2 on serum response factor-dependent luciferase gene activation.
Error bars represent standard error of the mean (SEM).
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749Figure 5. Mycro1 and Mycro2 Selectively
Reduce Anchorage-Independent Growth of
c-Myc-Transformed Rat1a Cells
Rat1a cells transformed with c-Myc (Rat1/c-
myc) or v-Src (Rat1a/v-src) were seeded in
soft agar and treated with the indicated con-
centration of test compounds. Colonies
larger than 0.13 mm in diameter were
counted. *p < 0.015 as compared to DMSO.
Error bars represent standard deviation (SD).expected to have only a minor effect on anchorage-in-
dependent growth of Rat1a/v-src cells, as has previ-
ously been observed with other c-Myc inhibitors [16,
17]. Neither Rat1a cells overexpressing c-Jun nor the
c-Myc target HMG-I/Y [31] formed a significant number
of colonies in soft agar in the time frame of the assay,
which prohibited their use as specificity controls.
Twenty micromolar Mycro1, and especially 20 mM My-
cro2, inhibited anchorage-independent growth of
Rat1a/c-myc cells, as observed by the significantly re-
duced number of large soft agar colonies (diameter >
0.13 mm) (Figure 5 and see Figure S3). In contrast,
only a minor reduction of the number of large soft agar
colonies formed by Rat1a/v-src cells was observed.
This indicates that Mycros inhibited c-Myc functions
only partially at concentrations up to 20 mM, as was ob-
served in vitro (Figure 2), and thereby selectively inter-
fere with the ability of Rat1a/c-myc cells to proliferate
anchorage independently. Derivative 3 had no effect
on c-Myc-dependent growth in soft agar, consistent
with its lack of activity in vitro and on gene transcription.
The selective effect of Mycros on c-Myc activity both
in vitro and in cellular systems could make them useful
research tools for the analysis of hitherto unresolved bi-
ological questions. Inhibition of c-Myc in tumor cell lines
by Mycros can be expected to downregulate expression
levels of c-Myc-regulated genes and could therefore be
used to complement the existing approaches toward
the identification of c-Myc target genes [1, 11]. Selective
inhibition of c-Myc by a cell-permeable agent could also
used to achieve a better understanding of the conditions
under which c-Myc promotes either proliferation or apo-
ptosis [32]. In a related application, Mycros could be
used to study the conditions under which tumors in-
duced by tissue-specific overexpression of c-Myc in an-
imal models [33] or by injection of c-Myc-transformed
cells in immunosuppressed mice can be reverted by
a pharmacological agent. Considering that Mycro1 and
Mycro2 completely fulfill Lipinski’s ‘‘rule of five’’ [24]
and that they display selective activity against c-Myc
in the low micromolar concentration range, it is well con-
ceivable that Mycros could serve as starting points for
drug discovery programs.
Significance
Transcription factorsof thebZip andbHLHLZip protein
families need to dimerize and bind to DNA in order to
exert most of their diverse biological functions. Theirdimerization occurs via a-helical domains, which gen-
erally do not contain obvious binding sites for small
molecules. Onemember of the bHLHZip protein family,
the oncoprotein c-Myc, is overexpressed in many
human tumors and is considered to be a potential ther-
apeutic target for the treatment of certain human tu-
mors. Since all biological activities of c-Myc known to
date require binding to its activation partner Max,
c-Myc can be inactivated by agents that block the
protein-protein interactions between c-Myc and Max.
We have identified two low-molecular weight com-
pounds, dubbed Mycro1 and Mycro2, which inhibit
c-Myc/Max dimerization in the lowmicromolar concen-
tration range. Mycro1 and Mycro2maintain their inhib-
itory activities in the presence of the c-Myc/Max DNA
bindingmotif and are the first inhibitors of Myc/Max di-
merization thatweredemonstrated to inhibitDNAbind-
ingof c-Myc/Max in vitrowith preference for c-Myc/Max
over relateddimeric transcription factors. BothMycro1
and Mycro2 exert c-Myc-dependent effects in cellular
assays. This selectivity represents a milestone in the
development of agents that specifically target the large
protein-protein interfaces between transcription factor
subunits and should make Mycros useful research
tools to address unresolved questions of c-Myc biol-
ogy. The data presented here demonstrate that the
dimerization of transcription factors can be potently
and specifically inhibited, even in the absence of obvi-
ous small-molecule binding pockets, by drug-likemol-
ecules in the low micromolar concentration range.
Experimental Procedures
Fluorescence Polarization Assays and High-Throughput
Screening
The sequence of the oligonucleotides used was as follows. c-Myc/
Max and Max/Max: 50-fluorophore-CACGTGGTCTGGG-30 and
50-CCCAGACCACGTG-30; 5-carboxyfluorescein was used as fluoro-
phore during screening, and Texas red was used as fluorophore
during validation and characterization. Jun/Jun: 50-Texas red-
ATGACTCATATCGGTCC-30 and 50-GGACCGATATGAGTCAT-30; C/
EBPa-C/EBPa: 50-Texas red-TTGCGCAATATCGGTC-30 and 50-GAC
CGATATTGCGCAA-30. Oligodeoxynucleotides were used at a final
concentration of 3 nM. Fluorescence polarization assays were per-
formed at final buffer concentrations of 60 mM Tris/HCl (pH 7.5),
150 mM NaCl, 9 mM MgCl2, 0.6 mM dithiothreitol, 3 mM EDTA,
0.1% Nonidet P-40, and 10% DMSO. Proteins only contained the
respective DNA binding and dimerization domains and were used at
a concentration close to their Kd-values (final concentrations: 5 nM
Myc/Max, 30 nM Max/Max, 30 nM Jun/Jun, 30 nM C/EBPa/C/
EBPa). Proteins were incubated with test compounds in Eppendorf
Chemistry & Biology
750tubes at room temperature for 1 hr prior addition of the respective la-
beled oligodeoxynucleotides. For the determination of Z0 [23], 5 nM
Myc/Max dimer was incubated for 1 hr with one equivalent of 9E10 an-
tibody, which inhibits Myc/Max dimerization by binding to the leucine
zipper of c-Myc, or the corresponding buffer without antibody. Three
independent experiments, in which the fluorescence polarization of
both the protein bound fluorescein-labeled oligodeoxynucleotide
(binding experiments without antibody) and the free fluorescein-la-
beled oligodeoxynucleotide (binding reaction containing 9E10) were
analyzed in 48 duplicate wells, were performed. 8,298 compounds
from Chemical Diversity and 9,000 compounds from Maybridge
were tested for their ability to interfere with c-Myc/Max dimerization
and DNA binding. Binding curves and inhibition curves were fitted
with SigmaPlot (SPSS Science Software GmbH). All competition
curves were repeated three times in independent experiments.
Chemical Compounds
Mycro1 (N-(4-methoxybenzyl)-5-(thiophen-2-yl)-7-(trifluoromethyl)-
pyrazolo[1,5-a]pyrimidine-2-carboxamide) and Mycro2 ((5-(thio-
phen-2-yl)-N-(thiophen-2-ylmethyl)-7-(trifluoromethyl)pyrazolo[1,5-
a]pyrimidine-2-carboxamide) were purchased from ChemDiv
(Mycro1, compound code 1762-0456; Mycro2, compound code
1762-0445). Compound 3 (5-(thiophen-2-yl)-N-(thiophen-2-ylmethyl)-
7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide) was
purchased from Asinex (compound code BAS 00923999).
Electrophoretic mobility shift assays (EMSA) were performed
essentially as described [16]. MycCFP (333 nM) and Max (333 nM)
were mixed in dimerization buffer (200 mM HEPES [pH 7.5], 500
mM KCl, 30 mM MgCl2, 2 mM DTT, 10 mM EDTA). To 18 ml of protein
mixture in an Eppendorf tube, 2 ml of 103 stock solutions of the test
compounds were added and incubated for 1 hr at room temperature
(final DMSO concentration: 10%). Subsequently, 10 ml of binding
buffer (33 mM HEPES [pH 7.5], 83 mM KCl, 5 mM MgCl2, 0.3 mM
DTT, 1.6 mM EDTA, 15 ng/ml poly dI/dC [Amersham], and 200,000
cpm of a freshly labeled, double-stranded DNA oligonucleotide
[50-AGTTGACCACGTGGTCTGGG-30]) were added. The sequence
of the mutated double-stranded oligonucleotide was 50-AGTTGAC
TACGTAGTCTGGG-30. Similarly, MBP-tagged v-Jun and v-Fos
(333 nM each) were incubated under otherwise identical conditions
with a double-stranded oligonucleotide comprising the TRE motif
(50-AGTCAGAATGACTCATATCGGTC-30). The sequence of the
mutated TRE oligonucleotide was 50-AGTCAGAAAGACTCTTATCG
GTC-30. Twenty minutes after addition of the binding buffer, pro-
tein-DNA complexes were resolved on a 4% acrylamide gel
(45 mM Tris-borate, 1 mM EDTA), and gels were dried before auto-
radiography. The intensities of the protein-DNA complexes were
compared to the intensities obtained from a standard curve of pro-
tein concentrations with SigmaPlot (SPSS Science Software GmbH).
GST Pull-Down Assays
For GST pull-down assays, 2 mg of recombinant, affinity-purified
GST-Max or GST alone were incubated with 30 ml of washed gluta-
thione-agarose beads in a total volume of 500 ml GST binding buffer
(5% glycerine, 5 mM Tris/HCl [pH 7.5], 50 mM NaCl, 0.5 mM DTT,
0.5 mM EDTA, 2.5% DMSO, 1% BSA) overnight at 4C with gentle
rotation. After washing the beads, recombinant, affinity-purified
Myc-CFP and 25 ml of a 203 stock of test compound or DMSO
were added in a total volume of 500 ml GST binding buffer. Samples
were again incubated overnight at 4C and washed. Beads were
boiled for 10 min in 40 ml of 33 La¨mmli buffer, and samples were
resolved by SDS-PAGE. Proteins were transferred to nitrocellulose
and probed with an anti-GFP antibody, followed by incubation
with horseradish peroxidase (HRP)-coupled secondary antibody.
Proliferation Assays
Growth curves were performed in 24-well tissue culture plates. Cells
were seeded at the following densities: NIH/3T3 cells, 2,000 cells/
well; U-2OS cells, 10,000 cells/well; MCF-7 cells, 10,000 cells/well;
Raji cells, 20,000 cells/well; PC-12 cells, 30,000 cells/well. Eight
hours later, each compound or DMSO (final concentration, 0.2%)
was added. Media containing the test compounds were replaced
on day three. Cells were trypsinized and manually counted at the
indicated times.BrdU Incorporation Assay
2,500 NIH/3T3 cells were seeded in 96-well microtiterplates. Eight to
10 hr later, the culture media was replaced with media containing
0.1% FCS and 10 mM of test compound or DMSO (final DMSO con-
centration, 0.3%). After 24 hr, cells were stimulated for 16 hr by
media containing 10% FCS in the presence of the test compounds.
Subsequently, cells were labeled with 100 mg/ml BrdU in media con-
taining 10% FCS for 4 hr. BrdU incorporation was monitored with the
5-Bromo-20-deoxy-uridine-Labeling and Detection Kit III (Roche Ap-
plied Science) according to the manufacturer’s instructions.
Luciferase Reporter Assays
108,000 HEK293 T cells were seeded in 12-well microtiter plates and
transfected with 500 ng reporter vector together with 375 ng full-
length c-Myc under the control of a CMV promoter and 12.8 ng of
pRL-CMV vector (Promega) with the calcium phosphate precipita-
tion technique. The reporter vectors carried either four E-box ele-
ments cloned into the pGL3 promoter vector (pGL3-E-Box) or four
mutated E boxes (pGL3-E-boxMut). To monitor AP-1-dependent
gene transcription, HEK293 T cells were transfected with either 10
ng of pAP-1-Luc (BD Biosciences, Clontech) or 10 ng of pAP1-
Mut-Luc, containing four mutated copies of the AP1 enhancer and
6.4 ng of pRL-CMV. Five hours after transfection, the media was re-
placed with fresh media containing the test compounds. For AP-1
luciferase assays, the fresh media contained an additional 10 ng/ml
of TPA (12-O-tetradecanoyl phorbol-13-acetate). For the SRF-de-
pendent luciferase assay, HEK293 T cells were cotransfected with
40 ng of the reporter vector 3D.ALuc [34] containing three SRF bind-
ing sites in the pGL3 framework, 50 ng of pEF.SRF.VP16 containing
SRF codons 1–412 fused to VP16 codons 410–490, or empty vector,
and 100 ng of pRL-TK vector (Promega). Luciferase assays were
performed with a Dual-Luciferase Reporter System (Promega) ac-
cording to the manufacturer’s instructions. Luciferase activities
were assessed 24 hr later.
Soft Agar Colony Assay
4,000 Rat1a/c-myc, Rat1a/v-src or Rat1a/pLXSN cells were sus-
pended in 200 ml of 0.2% agar containing MEM supplemented with
10% fetal bovine serum and 100 mg/ml penicillin/streptomycin, the
test compounds, or DMSO (final DMSO concentration, 1%) and
seeded on top of a 300 ml layer consisting of the same media con-
taining 0.7% agar in 24-well plates. Cells were fed every 3–4 days
by adding 100 ml 0.2% agar in the same medium containing the
appropriate compound concentration. Cells were stained after
10–14 days with 1 mg/ml iodonitrotetrazoliumchloride. Plates were
scanned, and colonies found to be larger than 0.13 mm by compar-
ison with a circular mask (Corel PhotoPaint) were counted.
Supplemental Data
Supplemental Data including the construction of the plasmids and
three experimental figures are available at http://www.chembiol.
com/cgi/content/full/13/7/745/DC1/.
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